Please provide your email address to receive an email when new articles are posted on . IntraFuse announced the United States Patent and Trademark office has granted ...
To determine if use of an osteogenic agent (rhBMP-2) at the time of surgical treatment for tibial pseudarthosis in NF1 patients will result in improved bone healing when compared to NF1 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results